[1] Pinkerton, J. V. (2023). Wechseljahre. MSD Manual Ausgabe für Patienten. https://www.msdmanuals.com/de/heim/gesundheitsprobleme-von-frauen/wechseljahre/wechseljahre
[2] Muhleisen, A. L., & Herbst-Kralovetz, M. M. (2016). Menopause and the vaginal microbiome. Maturitas, 91, 42–50. https://doi.org/10.1016/j.maturitas.2016.05.015
[3] Labrie, F., Archer, D. F., Koltun, W., Vachon, A., Young, D., Frenette, L., Portman, D., Montesino, M., Côté, I., Parent, J., Lavoie, L., Martel, C., Vaillancourt, M., Balser, J., & Moyneur, É. (2018). Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause, 25(11), 1339–1353. https://doi.org/10.1097/gme.0000000000001238
[4] Chen, J., Geng, L., Song, X., Li, H., Giordan, N., & Liao, Q. (2013). Evaluation of the efficacy and safety of hyaluronic acid vaginal gel to ease vaginal dryness: A multicenter, randomized, controlled, open‐label, parallel‐group, clinical trial. The Journal of Sexual Medicine, 10(6), 1575–1584. https://doi.org/10.1111/jsm.12125
[5] National Institute for Health and Care Excellence. (2015). Menopause: diagnosis and management (NICE guideline NG23). https://www.nice.org.uk/guidance/ng23/resources/menopause-diagnosis-and-management-pdf-1837330217413
[6] Frauengesundheitsportal.de. (2024). Mögliche Beschwerden in den Wechseljahren. https://www.frauengesundheitsportal.de/themen/wechseljahre/moegliche-beschwerden-in-den-wechseljahren/
[7] Inwald, E. C., Albring, C., Baum, E., Beckermann, M. J., Bühling, K. J., Emons, G., Gudermann, T., Hadji, P., Imthurn, B., Kiesel, L., Klemperer, D., Klose, P., König, K., Krüger, S., Langhorst, J., Leitzmann, M. F., Ludolph, A. C., Lüftner, D., & Neulen, J. (2021). Perimenopause and postmenopause – diagnosis and interventions. Geburtshilfe und Frauenheilkunde, 81(06), 612–636. https://doi.org/10.1055/a-1361-1948
[8] Gemeinsame Expertenkommission zur Einstufung von Stoffen. (2025). Stellungnahme 2025-01. Bundesinstitut für Arzneimittel und Medizinprodukte. https://www.bfarm.de/SharedDocs/Downloads/DE/Arzneimittel/Zulassung/ZulRelThemen/abgrenzung/Expertenkommission/stellungnahmen/2025-01.pdf
[9] Kalogeraki, A., Tamiolakis, D., Relakis, K., Karvelas, K., Froudarakis, G., Hassan, E., Martavatzis, N., Psaroudakis, E., Matalliotakis, J., Makrigiannakis, A., Koumantakis, E., & Delides, G. (1996). Cigarette smoking and vaginal atrophy in postmenopausal women. In vivo (Athens, Greece), 10(6), 597–600.
[10] Amabebe, E., & Anumba, D. O. C. (2018). Psychosocial Stress, Cortisol Levels, and Maintenance of Vaginal Health. Frontiers in endocrinology, 9, 568. https://doi.org/10.3389/fendo.2018.00568
[11] Brotman R. M. (2011). Vaginal microbiome and sexually transmitted infections: an epidemiologic perspective. The Journal of clinical investigation, 121(12), 4610–4617. https://doi.org/10.1172/JCI57172